Empowering Pharmaceutical Manufacturing Excellence

The Pharma University is a knowledge-driven community dedicated to advancing expertise in pharmaceutical manufacturing, validation, automation, engineering, and regulatory compliance. Our platform offers foundational courses, industry-focused blogs, and expert insights designed to equip professionals with the practical skills and regulatory knowledge needed to excel in a rapidly evolving industry.

Stay Updated With the Latest News

Your source for insights on emerging trends and regulatory updates shaping pharmaceutical manufacturing.

FDA Approves Vertex Pharmaceuticals' Non-Opioid Pain Medication

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' new non-opioid pain medication, Journavx (suzetrigine), for the treatment of moderate to severe acute pain in adults. This first-in-class analgesic targets sodium channels in the peripheral nervous system, offering an alternative to traditional opioid treatments and addressing concerns related to addiction and overdose. Common side effects include nausea, constipation, and headaches. Vertex plans to conduct further studies to explore additional applications of the drug.

FDA Approves Supernus Pharmaceuticals' Onapgo for Parkinson's Disease

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination, Onapgo, for treating movement-related symptoms in Parkinson's disease. Onapgo delivers apomorphine continuously under the skin, offering a more convenient alternative to frequent injections. In clinical trials, it reduced "off episodes"—periods when symptoms worsen—by more than two hours daily compared to less than an hour with a placebo. Supernus plans to launch Onapgo in the U.S. in the second quarter.